BRPI1016273A2 - método para a detecção de polimavírus jc - Google Patents

método para a detecção de polimavírus jc Download PDF

Info

Publication number
BRPI1016273A2
BRPI1016273A2 BRPI1016273-9A BRPI1016273A BRPI1016273A2 BR PI1016273 A2 BRPI1016273 A2 BR PI1016273A2 BR PI1016273 A BRPI1016273 A BR PI1016273A BR PI1016273 A2 BRPI1016273 A2 BR PI1016273A2
Authority
BR
Brazil
Prior art keywords
jcv
pml
patient
variant
sample
Prior art date
Application number
BRPI1016273-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Leonid Gorelik
Alexey Lugovskoy
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42542341&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1016273(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of BRPI1016273A2 publication Critical patent/BRPI1016273A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
BRPI1016273-9A 2009-02-05 2010-02-05 método para a detecção de polimavírus jc BRPI1016273A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15031009P 2009-02-05 2009-02-05
US61/150,310 2009-02-05
PCT/US2010/000342 WO2010090757A1 (en) 2009-02-05 2010-02-05 Methods for the detection of jc polyoma virus

Publications (1)

Publication Number Publication Date
BRPI1016273A2 true BRPI1016273A2 (pt) 2020-12-01

Family

ID=42542341

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1016273-9A BRPI1016273A2 (pt) 2009-02-05 2010-02-05 método para a detecção de polimavírus jc

Country Status (11)

Country Link
US (2) US20130101985A9 (enExample)
EP (1) EP2394163B1 (enExample)
JP (1) JP2012517017A (enExample)
CN (2) CN104316696A (enExample)
AU (1) AU2010210979B2 (enExample)
BR (1) BRPI1016273A2 (enExample)
CA (1) CA2751364C (enExample)
ES (1) ES2842425T3 (enExample)
NZ (1) NZ594973A (enExample)
SG (2) SG173201A1 (enExample)
WO (1) WO2010090757A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
AU2007224228B2 (en) 2006-03-03 2013-09-19 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2010090757A1 (en) 2009-02-05 2010-08-12 Biogen Idec Ma Inc. Methods for the detection of jc polyoma virus
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
PT2524060T (pt) 2010-01-11 2018-03-28 Biogen Ma Inc Ensaio para a deteção de anticorpos contra o vírus jc
PT3575792T (pt) 2011-05-31 2023-02-28 Biogen Ma Inc Método de avaliação do risco de lmp
PT2734544T (pt) 2011-07-18 2021-03-16 Us Health Métodos e composições para inibir a patologia associada a poliomavírus
EP2548567A1 (en) 2011-07-22 2013-01-23 Universitätsklinikum Hamburg-Eppendorf Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
EP2636746A1 (en) * 2012-03-06 2013-09-11 Life Science Inkubator A novel drug delivery system based on JCV-VLP
DK2828292T3 (da) 2012-03-20 2019-01-02 Biogen Ma Inc Jcv-neutraliserende antistoffer
DK2828284T3 (da) 2012-03-20 2019-06-11 Biogen Ma Inc Jcv-neutraliserende antistoffer
US9631243B2 (en) 2012-06-18 2017-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for identifying JC virus
CN104936980B (zh) 2012-12-31 2019-06-07 生物控股有限公司 用于治疗和预防多瘤病毒相关的疾病的重组人抗体
NO2774991T3 (enExample) * 2013-03-06 2018-05-05
US20160002743A1 (en) * 2013-03-15 2016-01-07 Biogen Ma Inc. High resolution melting analysis assay for the detection of viral dna
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHOD FOR ASSESSING A PML RISK
WO2015095770A1 (en) 2013-12-20 2015-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic jc polyomavirus compositions and methods of use
US20200197544A1 (en) * 2017-04-26 2020-06-25 Biogen Ma Inc. Jcv imaging methods and compositions
CN112442553A (zh) * 2020-10-27 2021-03-05 深圳市罗湖区人民医院 一种用于JCPyV检测与分型的试剂盒及方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3767755B2 (ja) * 1995-06-23 2006-04-19 エーザイ株式会社 抗ｊｃウイルス抗体
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
AU715973B2 (en) 1996-01-26 2000-02-10 Regents Of The University Of California, The Polymeric film, assay and method for direct colorimetric detection of analytes
DE10131145B4 (de) * 2001-06-28 2005-07-14 Innovent E.V. Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
JP4840792B2 (ja) 2001-11-22 2011-12-21 独立行政法人科学技術振興機構 ＪＣウイルスａｇｎｏを対象としたＰＭＬの治療
EP1785433A4 (en) 2004-07-01 2008-10-01 Tokyo Inst Tech VIRAL PARTICLE-LIKE CONSTRUCTION AND PROCESS FOR FORMING THE SAME IN PHYSIOLOGICAL CONDITIONS
JP4757103B2 (ja) 2005-06-13 2011-08-24 学校法人関西文理総合学園 試料中のウイルスを検出する方法およびシステム
US7468186B2 (en) 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
EP1951888B1 (en) 2005-11-09 2012-09-05 PrimeraDx, Inc. Multiplexed quantitative detection of pathogens
US7769230B2 (en) * 2006-11-30 2010-08-03 Eastman Kodak Company Producing low resolution images
WO2008077511A1 (en) 2006-12-22 2008-07-03 Karolinska Institutet Innovations Ab Human polyomavirus and methods of diagnosis and treatment
JP2008249433A (ja) 2007-03-29 2008-10-16 Kansai Bunri Sogo Gakuen 被験物質に対するプローブの結合親和性を測定する方法及びその利用
US20110118340A1 (en) 2008-02-08 2011-05-19 Muthiah Manoharan Delivery of rnai constructs to oligodendrocytes
WO2010090757A1 (en) 2009-02-05 2010-08-12 Biogen Idec Ma Inc. Methods for the detection of jc polyoma virus
EA201490368A1 (ru) 2011-07-29 2014-07-30 Байоджен Айдек Ма Инк. Анализ для определения днк вируса jc
AR095089A1 (es) 2013-01-30 2015-09-30 Biogen Idec Inc Ensayo de detección de adn de virus jc

Also Published As

Publication number Publication date
US9696307B2 (en) 2017-07-04
EP2394163B1 (en) 2020-08-19
US20120258443A1 (en) 2012-10-11
US20150219651A1 (en) 2015-08-06
US20130101985A9 (en) 2013-04-25
SG2014009120A (en) 2014-03-28
CN102369436B (zh) 2014-10-22
CA2751364C (en) 2017-06-20
SG173201A1 (en) 2011-08-29
AU2010210979A1 (en) 2011-09-22
AU2010210979B2 (en) 2015-12-10
EP2394163A1 (en) 2011-12-14
EP2394163A4 (en) 2012-08-01
WO2010090757A1 (en) 2010-08-12
CN102369436A (zh) 2012-03-07
ES2842425T3 (es) 2021-07-14
NZ594973A (en) 2012-05-25
CN104316696A (zh) 2015-01-28
JP2012517017A (ja) 2012-07-26
CA2751364A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
US9696307B2 (en) Methods for the detection of JC polyoma virus
Dang et al. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins
Flyak et al. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region
CN110964102B (zh) 能同时与犬、猫、水貂细小病毒结合的单克隆抗体、其可变区序列、杂交瘤细胞株及应用
Kailasan et al. Mapping antigenic epitopes on the human bocavirus capsid
CN103841993A (zh) 人肠道病毒特异性抗体及其在诊断中的应用
Hattori et al. The ACE2-binding interface of SARS-CoV-2 Spike inherently deflects immune recognition
Shang et al. NRP1 is a receptor for mammalian orthoreovirus engaged by distinct capsid subunits
EA029346B1 (ru) Моноклональное антитело человека против белка vp1 вируса jc
Kobayashi et al. Characterization and epitope mapping of monoclonal antibodies raised against rat hepatitis E virus capsid protein: An evaluation of their neutralizing activity in a cell culture system
JP5755239B2 (ja) Ｈ−１パルボウイルスに結合する抗体
Ssebyatika et al. Broadly neutralizing antibodies isolated from HEV convalescents confer protective effects in human liver-chimeric mice
WO2013043125A1 (en) Enterovirus 71 specific antibodies and uses thereof
Zhang et al. Development of a potential diagnostic monoclonal antibody against capsid spike protein VP27 of the novel goose astrovirus
Su et al. A human monoclonal antibody neutralizes SARS-CoV-2 Omicron variants by targeting the upstream region of spike protein HR2 motif
Byrnes et al. A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding
Xie et al. Orphan broadly RBD-binding antibodies annotate three remaining conserved RBD epitopes along SARS-CoV-2 evolution
BR112020015475A2 (pt) Molécula ligadora tendo atividade de neutralização contra o coronavírus que causa a síndrome respiratória do oriente médio
CN109212205B (zh) 伪狂犬病病毒gC蛋白抗体、含该抗体的试剂盒及应用
Wang et al. A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including Omicron
Matveev et al. Novel B-Cell Epitopes of Non-Neutralizing Antibodies in the Receptor-Binding Domain of the SARS-CoV-2 S-Protein with Different Effects on the Severity of COVID-19
Ha et al. Synthetic peptide-derived antibody-based immunohistochemistry for the detection of porcine circovirus 2 in pigs with postweaning multisystemic wasting syndrome
Kelley Investigating the Effects of Glycochenodeoxycholic Acid on Mutant Murine Norovirus P-Domain Structure and Antibody Interactions
Wang et al. Molecular blueprints of the Langya virus attachment and fusion glycoproteins
Valdés et al. A summary of the manufacture, biochemical characterization, and virological safety demonstration of the mouse mAb CB. Hep-1 used to produce the hepatitis B vaccine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25E Requested change of name of applicant rejected

Owner name: BIOGEN IDEC MA INC. (US)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 870160033268 DE01/07/2016 DEVIDO AO DESPACHO PUBLICADO NA RPI 2640 DE 10/08/2021.